Drug Profile
Research programme: TRPV1 receptor antagonists - Grunenthal/Medifron
Alternative Names: MDR-16523Latest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Medifron DBT
- Developer Grunenthal; Medifron DBT
- Class
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies; Postherpetic neuralgia
Most Recent Events
- 16 Jun 2022 Preclinical development in Diabetic-neuropathies is still underway in South Korea
- 16 Jun 2022 Preclinical development in Postherpetic-neuralgia is still underway in South Korea
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diabetic-neuropathies in South Korea